Rechallenge of anti‑PD‑1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report

Tan,Xiang; Kang,Le; Chen,Hao; Liu,Xingyan; Du,Chi

doi:10.3892/ol.2025.15098

Rechallenge of anti‑PD‑1 antibody combined with chemotherapy shows promising efficacy in the treatment of advanced metastatic hepatocellular carcinoma: A case report

Authors:
- Xiang Tan
- Le Kang
- Hao Chen
- Xingyan Liu
- Chi Du
View Affiliations

Affiliations: Department of Hematology and Oncology, The People's Hospital of An'yue, Ziyang, Sichuan 642350, P.R. China, Department of Oncology and Hematology, The People's Hospital of Dujiangyan, Chengdu, Sichuan 611132, P.R. China
Published online on: May 19, 2025 https://doi.org/10.3892/ol.2025.15098
Article Number: 352
Copyright: © Tan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This report presents the case of a 53‑year‑old man who was diagnosed with hepatocellular carcinoma and developed lung metastasis after undergoing surgery and interventional treatment. The lung metastasis progressed multiple times while the patient was undergoing successive treatments with Lenvatinib, Apatinib combined with Camrelizumab and Regorafenib. Eventually, a positive response was achieved with Tislelizumab combined with Xelox. The patient has been receiving Tislelizumab combined with Xelox for 23 months and has maintained a complete response to treatment. This case indicates that combining immune rechallenge with chemotherapy is beneficial for metastatic hepatocellular carcinoma.

View Figures

View References

1	Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX and Finn RS: Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 19:151–172. 2022. View Article : Google Scholar : PubMed/NCBI
2	Gobbini E, Charles J, Toffart AC, Leccia MT, Moro-Sibilot D and Giaj Levra M: Current opinions in immune checkpoint inhibitors rechallenge in solid cancers. Crit Rev Oncol Hematol. 144:1028162019. View Article : Google Scholar : PubMed/NCBI
3	Inno A, Roviello G, Ghidini A, Luciani A, Catalano M, Gori S and Petrelli F: Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 165:1034342021. View Article : Google Scholar : PubMed/NCBI
4	Kagohashi K, Miyazaki K, Shiozawa T and Satoh H: Pseudoprogression during successful rechallenge of immune checkpoint inhibitor in a NSCLC patient. Adv Respir Med. 89:316–319. 2021. View Article : Google Scholar : PubMed/NCBI
5	Plazy C, Hannani D and Gobbini E: Immune checkpoint inhibitor rechallenge and resumption: A systematic review. Curr Oncol Rep. 24:1095–1106. 2022. View Article : Google Scholar : PubMed/NCBI
6	Takemura K, Yamanaka T, Hayashida M, Kizawa R, Yamaguchi T, Tanabe Y, Sakaguchi K, Suyama K, Urakami S and Miura Y: Bell's palsy during rechallenge of immune checkpoint inhibitor. IJU Case Rep. 6:144–146. 2023. View Article : Google Scholar : PubMed/NCBI
7	Xu M, Hao Y, Shi Z and Song Z: Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 149:17987–17995. 2023. View Article : Google Scholar : PubMed/NCBI
8	Zaremba A, Eggermont AMM, Robert C, Dummer R, Ugurel S, Livingstone E, Ascierto PA, Long GV, Schadendorf D and Zimmer L: The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients. Eur J Cancer. 155:268–280. 2021. View Article : Google Scholar : PubMed/NCBI
9	Ren Z, Ducreux M, Abou-Alfa GK, Merle P, Fang W, Edeline J, Li Z, Wu L, Assenat E, Hu S, et al: Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): A multicenter, non-randomized, open-label, phase 2 trial. Liver Cancer. 12:72–84. 2022. View Article : Google Scholar : PubMed/NCBI
10	Boige V, Raoul JL, Pignon JP, Bouche O, Boucher E, Blanc JF, Seitz JF, Dupouy BN and Ducreux M; For the Fédération Francophone de Cancérologie Digestive, : Preliminary results of capecitabine-oxaliplatin (XELOX) in hepatocellular carcinoma (HCC): A phase II trial of the Fédération Francophone de Cancérologie Digestive (FFCD 2003-03 trial). J Clin Oncol. 23 (16 Suppl):S41282005. View Article : Google Scholar
11	Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng Z, Gu S, Wang L and Zou J: A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clin Oncol. 37 (15 Suppl):S40742019. View Article : Google Scholar
12	Bie F, Tian H, Sun N, Zang R, Zhang M, Song P, Liu L, Peng Y, Bai G, Zhou B and Gao S: Research progress of Anti-PD-1/PD-L1 immunotherapy related mechanisms and predictive biomarkers in NSCLC. Front Oncol. 12:7691242022. View Article : Google Scholar : PubMed/NCBI
13	Lin X, Zong C, Zhang Z, Fang W and Xu P: Progresses in biomarkers for cancer immunotherapy. MedComm (2020). 4:e3872023. View Article : Google Scholar : PubMed/NCBI
14	Chan YT, Zhang C, Wu J, Lu P, Xu L, Yuan H, Feng Y, Chen ZS and Wang N: Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 23:1892024. View Article : Google Scholar : PubMed/NCBI
15	Piñero F, Dirchwolf M and Pessôa MG: Biomarkers in hepatocellular carcinoma: Diagnosis, prognosis and treatment response assessment. Cells. 9:13702020. View Article : Google Scholar : PubMed/NCBI
16	O'Donnell JS, Long GV, Scolyer RA, Teng MWL and Smyth MJ: Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 52:71–81. 2017. View Article : Google Scholar : PubMed/NCBI
17	Syn NL, Teng MWL, Mok TSK and Soo RA: De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 18:e731–e741. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhang L, Geng Z, Hao B and Geng Q: Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody. Cancer Control. 29:107327482211112962022. View Article : Google Scholar : PubMed/NCBI
19	Vogel A, Meyer T, Sapisochin G, Salem R and Saborowski A: Hepatocellular carcinoma. Lancet. 400:1345–1362. 2022. View Article : Google Scholar : PubMed/NCBI
20	Liu L, Zheng YH, Han L and Qin SK: Efficacy and safety of the oxaliplatin-based chemotherapy in the treatment of advanced primary hepatocellular carcinoma: A meta-analysis of prospective studies. Medicine (Baltimore). 95:e49932016. View Article : Google Scholar : PubMed/NCBI